We attract distinguished and experienced industry professionals.
Our Scientific Advisory Board (SAB) works closely with the M6P Therapeutics’ leadership team to further advance research and development of the company’s innovative pipeline of lysosomal storage disorders (LSDs). By combining the substantial expertise of the SAB with the expertise of the company’s internal R&D team in enzyme replacement therapies and gene therapies, M6P Therapeutics is well positioned to rapidly advance its deep pipeline of LSD programs.
Nancy Dahms
Medical College of Wisconsin
Gregory Enns
Stanford School of Medicine
Stuart Kornfeld
Washington University. Co-Founder, M6P Tx & Chair, SAB
Mark Sands
Washington University
Anna Tylki-Szymanska
Children's Memorial Health Institute, Warsaw, Poland
Raymond Wang
University of California, Irvine School of Medicine
Nancy Dahms
Medical College of Wisconsin
Nancy Dahms, PhD, Professor of Biochemistry, Medical College of Wisconsin. Dr. Dahms worked in Dr. Stuart Kornfeld’s lab at Washington University in St. Louis where, along with another postdoc, she succeeded in cloning the cDNAs for the two mannose 6-phosphate receptors, the cation-independent (CI-) and cation-dependent (CD-) MPRs. These receptors play a central role in the transport of newly synthesized acid hydrolases from the Golgi to the lysosome. Most of the FDA-approved treatments for LSDs involve ERT that targets the CI-MPR for the uptake of recombinant acid hydrolases.
Gregory Enns
Stanford School of Medicine
Gregory Enns, MD, Professor of Pediatrics and Genetics at the Lucile Salter Packard Children’s Hospital Stanford School of Medicine. Dr Enns’ research interests include novel means of diagnosing and treating mitochondrial disorders, with an emphasis on antioxidant therapy, lysosomal disorders, and newborn screening by tandem mass spectrometry. His current pursuits include the analysis of glutathione and antioxidant status in patients who have mitochondrial disorders and the development of new techniques for diagnosing these
Stuart Kornfeld
Washington University. Co-Founder, M6P Tx & Chair, SAB
Stuart Kornfeld, co-founder of M6P Therapeutics, is a professor in the Department of Medicine and the Department of Biochemistry and Molecular Biophysics at Washington University Medical School. His lab discovered the mechanism whereby lysosomal enzymes acquire mannose 6-phosphate. Dr. Kornfeld has devoted decades to understanding mannose 6-phosphate and is considered the leading expert on this substance. He has advised multiple companies working on lysosomal storage disorders. He is a member of the National Academy of Sciences.
Mark Sands
Washington University
Mark S. Sands, PhD, Professor, Departments of Genetics and Medicine (Oncology & Stem Cell Biology). Dr. Sands runs an independent research laboratory with the goals of better understanding the underlying pathogenesis and developing effective therapies for inherited childhood diseases, specifically lysosomal storage diseases. One of the world’s leading authorities on the pathogenesis and treatment of lysosomal storage diseases, Dr. Sands is recognized for his exceptional work in providing an outstanding, nurturing training environment to postdoctoral students.
Anna Tylki-Szymanska
Children's Memorial Health Institute, Warsaw, Poland
Anna Tylki-Szymanska, MD, Professor, Department of Pediatrics and Metabolic Diseases, Children’s Memorial Health Institute, Warsaw, PL.
Raymond Wang
University of California, Irvine School of Medicine
Raymond Wang, MD, Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s, Associate Professor, Pediatrics, UC, Irvine School of Medicine. Dr. Wang is also a board-certified clinical geneticist and biochemical genetics specialist. He is investigating the role of inflammation and the innate immune system, triggered by arterial lysosomal storage, in promoting MPS cardiovascular disease, and identifying novel therapeutic methods to address treatment-refractory cardiovascular disease in MPS. He also actively works on other research projects related to Niemann-Pick C Disease, Pompe, Hunter, and Sanfillipo Syndrome.